Hofseth Biocare ASA Total Liabilities
Hofseth Biocare ASA total liabilities. Based on the latest financial reports, Hofseth Biocare ASA (HBC) has total liabilities worth Nkr419.19 Million NOK (≈ $44.11 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Hofseth Biocare ASA (HBC) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Hofseth Biocare ASA (2010–2024)
Total liabilities of Hofseth Biocare ASA from 2010 to 2024. This chart illustrates how Hofseth Biocare ASA's total liabilities have evolved over time, based on quarterly financial data. Explore Hofseth Biocare ASA strategic investment ratio to see how much of total assets are deployed in long-term investments.
Hofseth Biocare ASA Competitors by Total Liabilities
The table below lists competitors of Hofseth Biocare ASA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ene Technology Inc
TW:6243
|
Taiwan | NT$393.92 Million |
|
Nordic Resources Ltd
AU:NNL
|
Australia | AU$1.02 Million |
|
SelfWealth Limited
AU:SWF
|
Australia | AU$344.06 Million |
|
Botnia Gold AB (publ)
ST:BOTX
|
Sweden | Skr93.42 Million |
|
Yuhan Corp Preferred
KO:000105
|
Korea | ₩936.71 Billion |
|
AML3D Ltd
AU:AL3
|
Australia | AU$7.53 Million |
|
K Auction Inc.
KQ:102370
|
Korea | ₩93.59 Billion |
|
PTL LTD Ordinary Shares
NASDAQ:PTLE
|
USA | $425.73K |
Liability Composition Analysis (2010–2024)
This chart breaks down Hofseth Biocare ASA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see HBC current and non-current assets.
Liquidity & Leverage Metrics
Hofseth Biocare ASA Total Liabilities Ratios Explained
Hofseth Biocare ASA total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.30 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -15.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hofseth Biocare ASA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hofseth Biocare ASA (2010–2024)
The table below shows the annual total liabilities of Hofseth Biocare ASA from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Nkr280.07 Million ≈ $29.47 Million |
-19.75% |
| 2023-12-31 | Nkr348.98 Million ≈ $36.72 Million |
+32.69% |
| 2022-12-31 | Nkr263.00 Million ≈ $27.68 Million |
-4.57% |
| 2021-12-31 | Nkr275.60 Million ≈ $29.00 Million |
+41.06% |
| 2020-12-31 | Nkr195.37 Million ≈ $20.56 Million |
+11.47% |
| 2019-12-31 | Nkr175.26 Million ≈ $18.44 Million |
+71.99% |
| 2018-12-31 | Nkr101.90 Million ≈ $10.72 Million |
-30.75% |
| 2017-12-31 | Nkr147.16 Million ≈ $15.49 Million |
+39.10% |
| 2016-12-31 | Nkr105.79 Million ≈ $11.13 Million |
-34.21% |
| 2015-12-31 | Nkr160.80 Million ≈ $16.92 Million |
+15.75% |
| 2014-12-31 | Nkr138.92 Million ≈ $14.62 Million |
-2.89% |
| 2013-12-31 | Nkr143.05 Million ≈ $15.05 Million |
+32.55% |
| 2012-12-31 | Nkr107.92 Million ≈ $11.36 Million |
+185.20% |
| 2011-12-31 | Nkr37.84 Million ≈ $3.98 Million |
+103.55% |
| 2010-12-31 | Nkr18.59 Million ≈ $1.96 Million |
-- |
About Hofseth Biocare ASA
Hofseth BioCare ASA produces and sells health nutritional products for humans and pets in Norway, the United Kingdom, France, Belgium, Italy, Germany, rest of Europe, Japan, Asia, and the United States. The company offers ProGo, a bioactive peptide for weight management and metabolic health; OmeGo, a salmon oil that provides a full spectrum of fatty acids and omegas; CalGo and NT-II, which are ca… Read more